FLT3 and acute myeloid leukemia: In view of the limited growth inhibition observed with single-agent LY3009120 in FLT3-ITD-mutated AML cell lines, we asked whether the use of a tyrosine kinase inhibitor with FLT3 specificity such as sorafenib might augment the antileukemic effects of LY3009120.